13F Holdings
中文EN

ARVN ARVINAS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1655759 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-11.8%
TTM net income YoY83.8%
TTM EPS YoY90.1%
Revenue 3-yr CAGR18.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12.1%
Net margin-3.5%
FCF margin-58.0%
EBITDA margin-11.2%

Returns

ROE-1.8%
ROA-1.3%
ROIC (approx.)-5.9%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets15.4%
Debt / equity0.00x
Current ratio8.39x
Interest coverage—

Cash quality & payout

Operating cash flow / net income16.66x
Accruals ratio20.5%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$262.60M$263.40M$78.50M$131.40M$53.60M
R&D expense$285.20M$348.20M$379.70M$315.00M$180.40M
SG&A expense$95.90M$165.40M$100.30M$79.60M$61.60M
Operating income-$118.50M-$250.20M-$401.50M-$263.20M-$188.40M
Interest expense—$0$0$0$0
Pretax income-$80.50M-$198.30M-$363.90M-$251.00M-$184.10M
Income tax$300,000$600,000$900,000$20.90M$0
Net income-$80.80M-$198.90M-$367.30M-$282.50M-$191.00M
EBITDA-$115.50M-$245.60M-$396.70M-$256.90M-$183.60M
EPS (basic)-1.14-2.77-6.62-5.31-3.82
EPS (diluted)-1.14-2.77-6.62-5.31-3.82
Weighted avg. shares (diluted)70.90M71.90M55.50M53.20M50.00M
Balance sheet
Cash & equivalents$142.90M$100.50M$311.70M$86.80M$112.80M
Short-term investments$542.50M$938.90M$949.30M$1.12B$1.39B
Receivables$1.00M$5.70M$0$1.00M$15.00M
Current assets$700.70M$1.07B$1.28B$1.24B$1.55B
PP&E, net$5.20M$7.00M$11.50M$13.40M$12.70M
Total assets$717.90M$1.09B$1.30B$1.27B$1.58B
Current liabilities$142.50M$229.80M$257.10M$295.10M$261.70M
Short-term debt$200,000$200,000$200,000$0—
Long-term debt$400,000$600,000$800,000$1.00M$1.00M
Total debt$600,000$800,000$1.00M$1.00M$1.00M
Total liabilities$284.00M$529.70M$644.60M$703.90M$799.90M
Shareholders' equity$433.90M$561.70M$660.00M$564.90M$781.70M
Net debt-$142.30M-$99.70M-$310.70M-$85.80M-$111.80M
Shares outstanding63.50M68.80M68.00M53.20M53.00M
Cash flow statement
Operating cash flow-$273.80M-$259.30M-$347.80M-$273.50M$559.40M
Capital expenditure$1.90M$1.80M$2.90M$6.80M$4.70M
Free cash flow-$275.70M-$261.10M-$350.70M-$280.30M$554.70M
Investing cash flow$407.60M$34.70M$203.50M$242.80M-$1.31B
Financing cash flow-$91.40M$7.90M$374.70M$4.70M$278.60M
Depreciation & amortization$3.00M$4.60M$4.80M$6.30M$4.80M
Stock-based compensation$44.00M$88.20M$71.60M$75.50M$57.10M
Share buybacks$91.90M$0$0——

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.